生脉注射液联合丹参注射液治疗晚期肺癌合并冠心病的疗效观察

Efficacy of Shengmai injection combined with Danshen injection for the treatment of advanced lung cancer complicated with coronary heart disease

目的探讨生脉注射液联合丹参注射液治疗晚期肺癌合并冠心病的近远期临床疗效与安全性。方法选取2019年2月至2020年2月间上海市第四人民医院收治的82例晚期肺癌合并冠心病患者,随机抽签分为观察者和对照组,每组41例。对照组患者采用常规化疗及冠心病基础治疗,观察组患者在此基础上加用生脉注射液联合丹参注射液治疗,比较两组患者肺癌的近期疗效与冠心病的临床疗效、化疗不良反应发生情况及生活质量。结果观察组患者肺癌近期治疗总有效率为56.1%,高于对照组的31.7%,差异有统计学意义(P<0.05)。观察组患者冠心病治疗总有效率为95.1%,高于对照组的78.0%,差异有统计学意义(P<0.05)。观察组患者化疗不良反应率为17.1%,低于对照组的43.9%,差异有统计学意义(P<0.05)。治疗前,两组患者生活质量评分比较,差异无统计学意义(P>0.05);治疗后,观察组患者功能领域、症状领域和总体健康状况评分均高于对照组,差异均有统计学意义(均P<0.05)。结论晚期肺癌合并冠心病患者在常规治疗基础上采用生脉注射液联合丹参注射液治疗,可进一步抑制肿瘤,改善心功能,消除症状,且减少化疗不良反应,提高安全性,值得推广应用。

Objective To explore the short-and long-term clinical efficacy and safety of Shengmai injection combined with Danshen injection in the treatment of advanced lung cancer complicated with coronary heart disease.Methods Eighty-two patients with advanced lung cancer and coronary heart disease admitted to Shanghai Fourth People’s Hospital were selected between February 2019 and February 2020.They randomly divided into an observation group and a control group with 41 patients in each group.The observation group received Shengmai injection combined with Danshen injection besides conventional chemotherapy and the control group only received conventional chemotherapy and basic treatment for coronary heart disease.The short-term efficacy for lung cancer and the clinical efficacy for coronary heart disease,chemotherapy associated adverse reactions and quality of life were evaluated and compared between the two groups.Results The overall short-term efficacy for lung cancer was 56.1%in the observation group which was higher than 31.7%of the control group(P<0.05).The overall efficacy for coronary heart disease was95.1%in the observation group which was significantly higher than 78.0%of the control group(P<0.05).The rate of adverse reaction due to chemotherapy was 17.1%in the observation group which was significantly lower than 43.9%of the control group(P<0.05).There was no significant difference in score of quality of life between the groups before the treatment(P>0.05).After treatment,the scores of quality of life in the field of function,symptom and overall health status were significantly higher in the observation group than in the control group(all P<0.05).Conclusion For patients with advanced lung cancer and coronary heart disease,the combination treatment of Shengmai injection and Danshen injection on the basis of conventional treatment can further inhibit tumors,improve heart function,eliminate symptoms and reduce the side effects of chemotherapy and improve safety.It is worthy of promote and applications.